Abstract
In June 2002, the National Institute for Clinical Excellence (NICE) issued guidance on the use of new (atypical) antipsychotic drugs in the treatment of schizophrenia in England and Wales ( [National Institute for Clinical Excellence, 2002][1]). The guidance had a notional implementation time of 3
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
